BlackRock Inc. trimmed its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,781,958 shares of the biopharmaceutical company’s stock after selling 185,638 shares during the quarter. BlackRock Inc. owned about 8.24% of Amicus Therapeutics worth $118,646,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of FOLD. Teacher Retirement System of Texas lifted its stake in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 169 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in shares of Amicus Therapeutics in the second quarter worth $111,000. Aperio Group LLC lifted its stake in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,663 shares during the last quarter. Perennial Advisors LLC acquired a new stake in shares of Amicus Therapeutics in the second quarter worth $181,000. Finally, Principal Financial Group Inc. lifted its stake in shares of Amicus Therapeutics by 1.8% in the first quarter. Principal Financial Group Inc. now owns 26,883 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 487 shares during the last quarter.
FOLD has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. BidaskClub upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Robert W. Baird restated an “outperform” rating and issued a $12.00 price objective on shares of Amicus Therapeutics in a research note on Friday, June 30th. Chardan Capital restated a “buy” rating and issued a $16.50 price objective (down from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Finally, Leerink Swann restated an “outperform” rating and issued a $17.00 price objective (down from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Amicus Therapeutics presently has an average rating of “Buy” and a consensus price target of $17.81.
In other news, CEO John F. Crowley sold 449,295 shares of Amicus Therapeutics stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.33, for a total transaction of $6,438,397.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Daphne Quimi sold 7,000 shares of Amicus Therapeutics stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total value of $99,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 556,489 shares of company stock valued at $7,965,912. Company insiders own 3.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “BlackRock Inc. Has $118.65 Million Stake in Amicus Therapeutics, Inc. (FOLD)” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/10/18/blackrock-inc-has-118-65-million-stake-in-amicus-therapeutics-inc-fold.html.
Amicus Therapeutics, Inc. (FOLD) opened at 14.64 on Wednesday. The company’s 50-day moving average is $14.39 and its 200 day moving average is $10.90. Amicus Therapeutics, Inc. has a 1-year low of $4.41 and a 1-year high of $16.60. The firm’s market capitalization is $2.41 billion.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The firm had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same period in the previous year, the business posted ($0.40) earnings per share. On average, equities analysts expect that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.